Products - Metabolic conditions | Topic | NICE

Showing 16 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter
Status: PublishedRemove ‘Status: Published’ filter

Sodium zirconium cyclosilicate for treating hyperkalaemia (TA1148)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 April 2026
Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy (TA1115)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 December 2025
Fosdenopterin for treating molybdenum cofactor deficiency type A (terminated appraisal) (TA1078)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 June 2025
Somapacitan for treating growth hormone deficiency in people 3 to 17 years (TA1066)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 June 2025
Eplontersen for treating hereditary transthyretin-related amyloidosis (TA1020)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 November 2024
Burosumab for treating X-linked hypophosphataemia in adults (TA993)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 August 2024
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA984)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 June 2024
Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis (TA959)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 March 2024
Pegunigalsidase alfa for treating Fabry disease (TA915)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
4 October 2023
Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease (TA912)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 August 2023
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal) (TA867)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 February 2023
Vutrisiran for treating hereditary transthyretin-related amyloidosis (TA868)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 February 2023
Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal) (TA838)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 November 2022
Avalglucosidase alfa for treating Pompe disease (TA821)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 August 2022
Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 September 2021
Patiromer for treating hyperkalaemia (TA623)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 February 2020